Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

doi:10.1080/17512433.2017.1387051

Back to search

Article

Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis.

Expert review of clinical pharmacology - 1 Nov 2017

Kayser Sabine, Levis Mark J, Schlenk Richard F

Abstract excerpt

INTRODUCTION: A number of tyrosine kinase inhibitors (TKIs) have been developed that inhibit the constitutively activated kinase activity caused by activating tyrosine kinase mutations, such as FLT3 or KIT, thus interrupting signaling pathways. Currently, midostaurin is the only approved TKI as m...

Topics

Adult
Animals
Humans
Leukemia, Myeloid, Acute
Mastocytosis, Systemic
Mutation
Protein Kinase Inhibitors
Staurosporine
fms-Like Tyrosine Kinase 3

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.